# Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

> **NCT03268603** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 75 (actual)

## Conditions studied

- ALS
- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Autologous Adipose-derived Mesenchymal Stromal Cells

## Key facts

- **NCT ID:** NCT03268603
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-10
- **Primary completion:** 2024-01-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03268603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03268603, "Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03268603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*